Early Detection of Adverse Drug Reaction Signals by Association Rule Mining Using Large-Scale Administrative Claims Data
Overview
Affiliations
Introduction: Adverse drug reactions (ADRs) are a leading cause of mortality worldwide and should be detected promptly to reduce health risks to patients. A data-mining approach using large-scale medical records might be a useful method for the early detection of ADRs. Many studies have analyzed medical records to detect ADRs; however, most of them have focused on a narrow range of ADRs, limiting their usefulness.
Objective: This study aimed to identify methods for the early detection of a wide range of ADR signals.
Methods: First, to evaluate the performance in signal detection of ADRs by data-mining, we attempted to create a gold standard based on clinical evidence. Second, association rule mining (ARM) was applied to patient symptoms and medications registered in claims data, followed by evaluating ADR signal detection performance.
Results: We created a new gold standard consisting of 92 positive and 88 negative controls. In the assessment of ARM using claims data, the areas under the receiver-operating characteristic curve and the precision-recall curve were 0.80 and 0.83, respectively. If the detection criteria were defined as lift > 1, conviction > 1, and p-value < 0.05, ARM could identify 156 signals, of which 90 were true positive controls (sensitivity: 0.98, specificity: 0.25). Evaluation of the capability of ARM with short periods of data revealed that ARM could detect a greater number of positive controls than the conventional analysis method.
Conclusions: ARM of claims data may be effective in the early detection of a wide range of ADR signals.
Mohammad A, Hugtenburg J, Ceylan Y, Kooij M, Knies S, Van den Bemt P Int J Clin Pharm. 2025; .
PMID: 39954224 DOI: 10.1007/s11096-025-01873-8.
Wang J, Zhao Y, Chen Z, Huang R Front Pharmacol. 2025; 15():1451713.
PMID: 39845792 PMC: 11751046. DOI: 10.3389/fphar.2024.1451713.
Naseralallah L, Nasrallah D, Koraysh S, Aboelbaha S, Hussain T Clin Pharmacol. 2024; 16:33-40.
PMID: 39677557 PMC: 11646396. DOI: 10.2147/CPAA.S487288.
Yang J, Hu Z, Zhang L, Peng B Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065673 PMC: 11279999. DOI: 10.3390/ph17070822.